Ipsen Paddington
Pharma-Exclusive Webinar: Redefining Engagement in the AI Era
Join Impetus Digital's pharma-exclusive webinar to discover how compliant AI tools and virtual workflows can elevate static programs into high-retention, interactive experiences without enterprise overhead.
Ipsen’s cabozantinib accepted by SMC for adults with advanced neuroendocrine tumours
NETs affect approximately seven per 100,000 people in Scotland
Ipsen to acquire Memo Therapeutics in deal worth more than €700m
The deal expands the company’s rare disease portfolio
Amiculum joins Bionow: supporting collaboration across the life sciences sector in the North of the UK
We’re delighted that Amiculum has become a member of Bionow, joining a collaborative community that plays an important role in bringing together life sciences organizations across the North of the...
Ipsen appoints Michelle Werner as Executive Vice President, President of North America
Werner previously held senior roles at Bristol Myers Squibb, AstraZeneca and Novartis
Amiculum reaffirms presence in Dundee with new office and continued academic partnership
Amiculum is pleased to announce the relocation of its Dundee team to a new, state-of-the-art facility at the Dundee Life Sciences Innovation Hub, an environment designed to accelerate scientific progress...
British Chambers of Commerce partners with Singapore to scale up UK imports
The Singapore Life Sciences Trade Accelerator six-month pilot programme aims to increase export opportunities
Ipsen appoints Pierrick Lefranc as Executive Vice President Technical Operations
Lefranc has served at Ipsen since 2013, most recently as Senior Vice President
Ipsen to acquire ImCheck Therapeutics in a deal worth up to €1bn
The acquisition includes a clinical stage acute myeloid leukaemia treatment currently in phase 1/2 trials
Ipsen’s tumour treatment receives MHRA marketing authorisation
This is the first approval in the UK for previously treated advanced neuroendocrine tumours
New centre for life sciences launched in London
Victoria House is a state-of-the-art life sciences hub
Ipsen receives EC approval for Cabometyx in advanced neuroendocrine tumours
Treatment options following disease progression have previously been limited for many patients